|

AB-101 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ALLONK, CYCLOPHOSPHAMIDE, FLUDARABINE, RITUXIMAB

Pipeline

Phase 1: 1

Top Sponsors

  • IRIS Research and Development, LLC1

Indications

  • Granulomatosis With Polyangiitis1
  • Pemphigus Vulgaris1
  • Systemic Lupus Erythematosus1
  • Lupus1
  • Arthritis1

Plantation, Florida1 trial

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

IRIS Research and Development, LLC

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.